NASDAQ$VIR
Vir Biotechnology Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year ended December 31, 2023.
Vir Biotechnology reported a net loss of $116 million for the fourth quarter of 2023, with total revenues of $16.8 million. The company's cash, cash equivalents, and investments stood at $1.63 billion as of December 31, 2023. The company is focusing its capital allocation on programs with the highest potential for patient impact and value creation.
- SOLSTICE trial on track to complete enrollment ahead of schedule with initial data expected in the second quarter.
- Phase 2 MARCH Part B chronic hepatitis B data demonstrated that tobevibart may play an important role in achieving a functional cure; 48-week end of treatment data readout on track for the fourth quarter.
- Cash, cash equivalents and investments totaled $1.63 billion as of December 31, 2023.
- Strategic imperatives to focus its capital allocation on programs with the highest potential for patient impact and value creation.
Headline financials
Revenue & EPS history
Vir · Revenue · Quarterly
$16.8M
Revenue by segment
Vir · $2.35M total across 2 segments · Q3 2023
- Grant revenue$6.74M+117.3%286.7%
- License & collaboration revenue-$4.39M-101.4%-186.7%
Forward guidance
Vir is providing full year 2024 guidance below (in millions): GAAP combined R&D and SG&A expense range:$650 to$680
Tailwinds
- GAAP combined R&D and SG&A expense range:$650 to$680
- Stock-based compensation expense included in the GAAP combined R&D and SG&A expense range: $115 to $105
- Restructuring charges included in the GAAP combined R&D and SG&A expense range: $35 to $25
- Approximately three to four percent of the GAAP combined R&D and SG&A expense will be funded by grants.
- These grants are recognized as revenue.
Headwinds
- The GAAP combined R&D and SG&A expense guidance does not include the effect of GAAP adjustments caused by events that may occur subsequent to the publication of this guidance, including, but not limited to, business development activities, litigation, in-process R&D impairments, and changes in the fair value of contingent considerations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+2.0%
Avg return
Earnings day
-0.4%
Avg return
5 days after
-1.3%
Avg return
30 days after
43%
12 / 28 earnings
Positive
+27.7%
Q4 2025
Best reaction
-15.1%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.8% | -7.2% | -13.7% | |
| Q4 2025 | +27.7% | +22.3% | +20.6% | |
| Q3 2025 | -5.6% | -8.9% | +8.3% | |
| Q1 2025 | -3.4% | -16.2% | -2.9% | |
| Q4 2024 | -11.8% | -10.9% | -27.2% | |
| Q3 2024 | +21.8% | +26.8% | +4.7% | |
| Q2 2024 | -9.4% | -15.4% | -18.7% | |
| Q1 2024 | +18.9% | +13.6% | +17.5% | |
| Q4 2023 | +14.0% | +13.1% | -0.6% | |
| Q3 2023 | +12.5% | +8.3% | +24.4% | |
| Q2 2023 | -3.0% | -4.8% | -10.9% | |
| Q1 2023 | -3.5% | -4.5% | +7.5% | |
| Q4 2022 | -14.8% | -15.6% | -16.7% | |
| Q3 2022 | +15.0% | +20.3% | +23.7% | |
| Q2 2022 | +2.0% | -4.9% | -25.9% | |
| Q1 2022 | -3.1% | -1.4% | +12.5% | |
| Q4 2021 | +0.1% | -13.7% | -21.5% | |
| Q3 2021 | -15.1% | -11.7% | +20.4% | |
| Q2 2021 | +3.3% | +10.5% | +32.0% | |
| Q1 2021 | -1.0% | -8.5% | +3.5% | |
| Q4 2020 | -4.2% | -11.7% | -21.2% | |
| Q3 2020 | +8.2% | +5.8% | +26.0% | |
| Q2 2020 | -0.6% | -0.9% | -46.8% | |
| Q2 2019 | -0.6% | -0.9% | -46.8% | |
| Q1 2020 | -1.9% | -3.1% | +7.2% | |
| Q1 2019 | -1.9% | -3.1% | +7.2% | |
| Q4 2019 | +11.5% | +11.4% | +6.0% | |
| Q3 2019 | -3.0% | -0.5% | -3.7% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro